title: Costs, effects and C/E-ratios alongside a clinical trial.
abstract: A general approach is discussed to assess the uncertainty surrounding the cost effectiveness ratio (C/E-ratio) estimated on the basis of data from a randomised clinical trial. The approach includes the calculation of a 95% probability ellipse and introduces the concept of a so called C/E-acceptability curve. This last curve defines for each predefined C/E-ratio the probability that the C/E-ratio found in the study is acceptable. The approach is illustrated by estimates of costs per life saved and costs per patient discharged alive on the basis of data from a phase II trial addressing the value of anakinra in treating sepsis syndrome.
authors: Institute for Medical Technology Assessment, Erasmus University Rotterdam, The Netherlands.
authors: B A
authors: BA
authors: van Hout
authors: M J
authors: MJ
authors: Al
authors: G S
authors: GS
authors: Gordon
authors: F F
authors: FF
authors: Rutten
mesh_terms: D003362:Cost-Benefit Analysis; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein; D018803:Models, Economic; D016032:Randomized Controlled Trials as Topic / Q000191:economics*; D012795:Sialoglycoproteins / Q000191:economics / Q000627:therapeutic use; D018746:Systemic Inflammatory Response Syndrome / Q000188:drug therapy / Q000191:economics; D026712:Value of Life
chemical_list: C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D012795:Sialoglycoproteins